## ULTA: Ulta Beauty, Inc. - XLY: Consumer Cyclical

### Executive Summary

No thesis match: MRS_10 2.4% below STRENGTH zone (3.0-6.0%); PEG 2.52 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($549.68)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 5, Bearish: 2)

**1. Ulta Beauty (ULTA): Revisiting Valuation After a Strong Share Price Run**
- Source: Simply Wall Street | 20251217T040854 | Neutral | Relevance: 100%
- Ulta Beauty (ULTA) has seen a strong share price run, outperforming broader retail with an 11% climb over the past month and high 30s year-to-date gains. While its narrative fair value suggests it's 2.3% undervalued at $603, market ratios flash caution with the stock trading at 22 times earnings, higher than the US specialty retail average of 20.3 times. Investors are questioning whether Ulta still offers mispriced growth or if its future potential is already priced in, especially considering risks like persistent wage inflation and the potential loss of its Target partnership.

**2. DRMTLGY Makes Retail Debut Through Exclusive Launch at Ulta Beauty**
- Source: PR Newswire | 20251217T150210 | Bullish | Relevance: 100%
- DRMTLGY, a clinical skincare brand, is launching exclusively at Ulta Beauty in nearly all 1,400+ stores nationwide and on Ulta.com starting December 26. This partnership aims to make high-performance, dermatologist-trusted formulations more accessible to consumers. The lineup will feature 13 of DRMTLGY's most popular products, including serums, creams, cleansers, and SPF.

**3. Zacks Research Boosts Earnings Estimates for Ulta Beauty**
- Source: MarketBeat | 20251217T135053 | Bullish | Relevance: 100%
- Zacks Research has increased its Q4 2026 EPS estimate for Ulta Beauty to $7.68 and provided new forecasts for FY2027 and FY2028 earnings. Several brokers have also raised their price targets, contributing to a "Moderate Buy" consensus rating for ULTA stock. The company recently surpassed quarterly earnings expectations and provided strong FY2025 guidance.

**4. Baird Adjusts Price Target on Ulta Beauty to $700 From $670, Maintains Outperform Rating**
- Source: marketscreener.com | 20251217T113750 | Bullish | Relevance: 100%
- Baird has increased its price target for Ulta Beauty (ULTA) to $700 from $670, while reiterating an Outperform rating on the stock. This adjustment reflects an updated outlook on the company. The article also notes recent adjustments to Ulta Beauty's price targets by other analytical firms.

**5. Drmtlgy Joins Ulta Beautyâ€™s Roster**
- Source: WWD | 20251217T050454 | Bullish | Relevance: 100%
- Ulta Beauty is expanding its dermatological skin care offerings by adding Drmtlgy to its assortment, with a launch planned for December 26 in nearly all 1,400-plus stores and online. The brand will introduce 13 of its top-selling products, ranging from $28 to $69, aiming to make clinically proven results accessible to a broader customer base. Ulta Beauty highlighted the importance of customer sophistication in skincare and Drmtlgy's unique blend of dermatological credibility and modern accessibility as a natural fit.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 13, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Oppenheimer | $675 | $615 | +10% |
| 2025-12-08 | Morgan Stanley | $640 | $600 | +7% |
| 2025-12-08 | TD Cowen | $725 | $600 | +21% |
| 2025-12-05 | DA Davidson | $650 | $625 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Oppenheimer | main | Outperform |
| 2025-12-08 | Morgan Stanley | main | Overweight |
| 2025-12-08 | TD Cowen | up | Buy |
| 2025-12-05 | DA Davidson | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 1 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.6%)
- Blackrock Inc.: 9.0% (-2.1%)
- JPMORGAN CHASE & CO: 5.5% (+99.0%)
- State Street Corpora: 4.4% (+2.3%)
- Sanders Capital, LLC: 2.8% (+8.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 13 raises (avg +6%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.52 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 48%, ROA 15%). Analyst sentiment positive (13 raises, avg +6%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.3B |
| Beta | 0.87 |
| 52W Range | $309.01 - $611.90 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.52 |
| Forward P/E | 20.8 |
| Current P/E | 23.0 |
| YoY Growth | 10.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.7% to 2.4% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.6pp (needs >3.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (2.71), confirming momentum. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.36% (CS: 48) | Neutral |
| RSI_14 | 60.8 | Neutral |
| MACD Histogram | 2.71 | Bullish |
| vs SMA20 | 1.051x | Above |
| vs SMA50 | 1.087x | Above |
| vs SMA200 | 1.235x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $585.98
- **Stop Loss:** $549.68 (6.2% risk)
- **Target:** $622.28 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 29
- **Position Value:** $16,993.42
- **Portfolio %:** 16.99%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | MOMENTUM (Zone F) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-03-12 (Est: $7.15)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $4.60 | $5.14 | +11.8% |
| 2025Q3 | $5.04 | $5.78 | +14.6% |
| 2025Q2 | $5.80 | $6.70 | +15.5% |
| 2025Q1 | $7.15 | $8.46 | +18.4% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*